Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

NCT01040832 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01040832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01040832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Lead sponsor
EMD Serono
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2009
Completion date
Not reported
Enrollment
107 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck cancer